Carsten Denkert - Nanotechnology

Author Information

Carsten Denkert is affiliated with the Institute of Pathology at Charité Universitätsmedizin Berlin, located at Charitéplatz 1, 10117, Berlin, Germany. With a significant focus on pathology, Denkert contributes extensively to cancer research, particularly in breast and ovarian cancer studies.

Research Contributions

Carsten Denkert has made substantial contributions to cancer research, with a particular emphasis on breast cancer treatment and pathology. His work includes studies on molecular plasticity in luminal breast cancer, tumor infiltrating lymphocytes in early-stage triple-negative breast cancer, and potential therapeutic targets in mucinous ovarian cancer. Denkert has also explored the efficacy of various systemic therapies and treatment strategies, such as CDK 4/6 inhibitors and antibody-drug conjugates, in improving patient outcomes.

Aliases

Carsten Denkert is also known by several aliases including C Denkert and C. Denkert.

Publication and Citation Metrics

Citation Count	38,083
H-index	91
Paper Count	708

Publications:

Abstract PD2-04: Molecular plasticity of luminal breast cancer and response to CDK 4/6 inhibition - The biomarker program of the PENELOPE-B trial investigating post-neoadjuvant palbociclib

DOI: 10.1158/1538-7445.sabcs21-pd2-04

Year: 2022

Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer

DOI: 10.1038/s41523-021-00362-1

Year: 2022

Polycomb Protein BMI-1 as a Potential Therapeutic Target in Mucinous Ovarian Cancer

DOI: 10.21873/anticanres.15650

Year: 2022

Abstract OT1-02-01: Phase III postneoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment - SASCIA

DOI: 10.1158/1538-7445.sabcs21-ot1-02-01

Year: 2022

Abstract PD9-07: Mdm2 gene amplification in estrogen receptor-positive breast cancer cells is associated with enhanced solid tumor growth and pronounced metastatic potential in humanized tumor mice (HTM) and a poor outcome of patients with luminal breast cancer

DOI: 10.1158/1538-7445.sabcs21-pd9-07

Year: 2022

Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial

DOI: 10.3390/cancers14030521

Year: 2022

Abstract P2-12-03: Phenotype shifting in early breast cancer with and without primary systemic treatment: A retrospective cohort analysis correlating core needle biopsies and excisional biopsies in 1250 consecutive real-world cases

DOI: 10.1158/1538-7445.sabcs21-p2-12-03

Year: 2022

Practice-Changing Perspectives regarding Systemic Therapy in Early Breast Cancer: Opinions of German Experts regarding the 17th St. Gallen International Consensus Conference

DOI: 10.1159/000517501

Year: 2022

Pembrolizumab vs placebo + chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs placebo as adjuvant treatment for early triple-negative breast cancer (TNBC): Phase 3 KEYNOTE-522 study

DOI: 10.1016/j.ejso.2021.12.430

Year: 2022

Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood

DOI: 10.1007/s00262-022-03166-9

Year: 2022

How does cost factor into the limitations of nanotechnology instrumentation?

How is Electric Charge Measured at the Nanoscale?

What are the Applications of Viruses in Drug Delivery?

What Techniques are Used to Measure Electrostatic Charge at the Nanoscale?

How Do Startups Benefit from Collaboration?

How is Experimental Data Analyzed?

What is the Future of Nanotechnology in Wearable Devices?

What are Nano-Enabled Cryptographic Algorithms?

Why Are Regulations Important?

How Important Is Public Perception for Commercialization?

Partnered Content Networks

Relevant Topics